09 - References

References

Schizophrenia and related psychoses CHAPTER 1 References

1. Dudley K, et al. Chlorpromazine dose for people with schizophrenia. Cochrane Database Syst Rev 2017; 4(4):CD007778.
2. McGorry PD. Recommended haloperidol and risperidone doses in first-­episode psychosis. J Clin Psychiatry 1999; 60:794–795.
3. Schooler N, et  al. Risperidone and haloperidol in first-­episode psychosis: a long-­term randomized trial. Am J Psychiatry 2005; 162:947–953.
4. Donnelly L, et al. Haloperidol dose for the acute phase of schizophrenia. Cochrane Database Syst Rev 2013; (8):CD001951.
5. Oosthuizen P, et al. A randomized, controlled comparison of the efficacy and tolerability of low and high doses of haloperidol in the treatment of first-­episode psychosis. Int J Neuropsychopharmacol 2004; 7:125–131.
6. Leucht S, et  al. Dose equivalents for second-­generation antipsychotics: the minimum effective dose method. Schizophr Bull 2014; 40:314–326.
7. Soares BG, et al. Sulpiride for schizophrenia. Cochrane Database Syst Rev 2000; (2):CD001162.
8. Armenteros JL, et al. Antipsychotics in early onset schizophrenia: systematic review and meta-­analysis. Eur Child Adolesc Psychiatry 2006; 15:141–148.
9. Koch K, et al. Trifluoperazine versus placebo for schizophrenia. Cochrane Database Syst Rev 2014; (1):CD010226.
10. Sparshatt A, et al. Amisulpride -­ dose, plasma concentration, occupancy and response: implications for therapeutic drug monitoring. Acta Psychiatr Scand 2009; 120:416–428.
11. Buchanan RW, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010; 36:71–93.
12. Cutler AJ, et al. The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia. CNS Spectr 2006; 11:691–702.
13. Mace S, et al. Aripiprazole: dose–response relationship in schizophrenia and schizoaffective disorder. CNS Drugs 2008; 23:773–780.
14. Sparshatt A, et al. A systematic review of aripiprazole: dose, plasma concentration, receptor occupancy and response: implications for therapeutic drug monitoring. J Clin Psychiatry 2010; 71:1447–1456.
15. Liu CC, et al. Aripiprazole for drug-­naive or antipsychotic-­short-­exposure subjects with ultra-­high risk state and first-­episode psychosis: an open-­label study. J Clin Psychopharmacol 2013; 33:18–23.
16. Leucht S, et al. Dose-­response meta-­analysis of antipsychotic drugs for acute schizophrenia. Am J Psychiatry 2020; 177:342–353.
17. Citrome L. Role of sublingual asenapine in treatment of schizophrenia. Neuropsychiatr Dis Treat 2011; 7:325-­339.
18. Tenjin T, et al. Profile of blonanserin for the treatment of schizophrenia. Neuropsychiatr Dis Treat 2013; 9:587–594.
19. Correll CU, et  al. Efficacy of brexpiprazole in patients with acute schizophrenia: review of three randomized, double-­blind, placebo-­ controlled studies. Schizophr Res 2016; 174:82–92.
20. Antoun Reyad A, et al. Efficacy and safety of brexpiprazole in acute management of psychiatric disorders: a meta-­analysis of randomized controlled trials. Int Clin Psychopharmacol 2020; 35:119–128.
21. Garnock-­Jones KP. Cariprazine: a review in schizophrenia. CNS Drugs 2017; 31:513–525.
22. Citrome L. Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-­based review and place in therapy. Neuropsychiatr Dis Treat 2018; 14:2563–2577.
23. Lokshin P, et al. Clotiapine: an old neuroleptic with possible clozapine-­like properties. Progr Neuro Psychopharmacol Biol Psychiatry 1998; 22:1289–1293.
24. Lyseng-­Williamson K. Clotiapine in schizophrenia: a guide to its use. Drugs Ther Perspect 2015; 31:365–371.
25. Crabtree BL, et al. Iloperidone for the management of adults with schizophrenia. Clin Ther 2011; 33:330–345.
26. Peng H, et al. Efficacy and safety of lumateperone for bipolar depression and schizophrenia: a systematic review and meta-­analysis. Int J Neuropsychopharmacol 2024; 27:pyae052.
27. Meltzer HY, et al. Lurasidone in the treatment of schizophrenia: a randomized, double-­blind, placebo-­ and olanzapine-­controlled study. Am J Psychiatry 2011; 168:957–967.
28. Sanger TM, et al. Olanzapine versus haloperidol treatment in first-­episode psychosis. Am J Psychiatry 1999; 156:79–87.
29. Kasper S. Risperidone and olanzapine: optimal dosing for efficacy and tolerability in patients with schizophrenia. Int Clin Psychopharmacol 1998; 13:253–262.
30. Keefe RS, et al. Long-­term neurocognitive effects of olanzapine or low-­dose haloperidol in first-­episode psychosis. Biol Psychiatry 2006; 59:97–105.
31. Bishara D, et al. Olanzapine: a systematic review and meta-­regression of the relationships between dose, plasma concentration, receptor occupancy, and response. J Clin Psychopharmacol 2013; 33:329–335.
32. Mathis MV, et al. The US Food and Drug Administration’s perspective on the new antipsychotic pimavanserin. J Clin Psychiatry 2017; 78:e668–e673.
33. Ballard C, et al. Pimavanserin in Alzheimer’s disease psychosis: efficacy in patients with more pronounced psychotic symptoms. J Prev Alzheimers Dis 2019; 6:27–33.
34. Nasrallah HA, et al. Successful treatment of clozapine-­nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-­2A receptor inverse agonist. Schizophr Res 2019; 208:217–220.
35. Sparshatt A, et al. Quetiapine: dose–response relationship in schizophrenia. CNS Drugs 2008; 22:49–68.
36. Sparshatt A, et al. Relationship between daily dose, plasma concentrations, dopamine receptor occupancy, and clinical response to quetiapine: a review. J Clin Psychiatry 2011; 72:1108–1123.
37. Pagsberg AK, et al. Quetiapine extended release versus aripiprazole in children and adolescents with first-­episode psychosis: the multicentre, double-­blind, randomised tolerability and efficacy of antipsychotics (TEA) trial. Lancet Psychiatry 2017; 4:605–618.

10 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 1 38. Terao I, et al. Comparative efficacy of quetiapine by dose and formulation for psychosis in schizophrenia: a systematic review and dose-­ response model-­based network meta-­analysis. J Psychopharmacol 2023; 37:953–959. 39. Lane HY, et al. Risperidone in acutely exacerbated schizophrenia: dosing strategies and plasma levels. J Clin Psychiatry 2000; 61:209–214. 40. Williams R. Optimal dosing with risperidone: updated recommendations. J Clin Psychiatry 2001; 62:282–289. 41. Ezewuzie N, et  al. Establishing a dose-­response relationship for oral risperidone in relapsed schizophrenia. J Psychopharmacol 2006; 20:86–90. 42. Li C, et al. Risperidone dose for schizophrenia. Cochrane Database Syst Rev 2009; (4):CD007474. 43. Kaul I, et al. Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-­trospium) in schizophrenia (EMERGENT-­2) in the USA: results from a randomised, double-­blind, placebo-­controlled, flexible-­dose phase 3 trial. Lancet 2024; 403:160–170. 44. Kaul I, et al. Efficacy of xanomeline and trospium chloride in schizophrenia: pooled results from three 5-­week, randomized, double-­blind, placebo-­controlled, EMERGENT trials. Schizophrenia (Heidelb) 2024; 10:102. 45. Bagnall A, et al. Ziprasidone for schizophrenia and severe mental illness. Cochrane Database Syst Rev 2000; (4):CD001945. 46. Taylor D. Ziprasidone: an atypical antipsychotic. Pharmaceutical J 2001; 266:396401. 47. Joyce AT, et al. Effect of initial ziprasidone dose on length of therapy in schizophrenia. Schizophr Res 2006; 83:285–292.